Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-duration ibrutinib + obinutuzumab in treatment-naïve CLL
2024-514824-18-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Bone marrow MRD negativity rate at 30 days post-therapy. Planned start Aug 2024; status: authorised.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-514824-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514824-18-00.